Jazz’s cannabidiol therapy flunks in Japanese Phase III trial

[cafead]

via Jazz Pharmaceuticals’ efforts to get its cannabidiol therapy approved in Japan have hit a snag after a Phase III trial in Japan evaluating the therapy failed to meet its primary endpoint.

article source